間欠性跛行の世界市場レポート 2025年

間欠性跛行市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.2％で、173億9,000万米ドルに成長します。予測期間中の成長は、糖尿病の有病率の増加、肥満率の上昇、心血管疾患の有病率の増加、アルコールとタバコの消費量の増加、ヘルスケア支出の増加といった要因に起因しています。予測期間における主な動向としては、PAD診断の進歩、ウェアラブルデバイスの統合、個別化医療の導入、薬剤溶出ステントへのシフト、幹細胞治療の進歩などが挙げられます。

末梢動脈疾患（PAD）の罹患率の上昇は、今後数年間の間欠性跛行市場の成長を牽引すると予想されます。PADは、動脈が狭くなることで手足の血流が減少し、痛みやしびれなどの合併症を引き起こす循環器系の疾患です。PAD症例の増加は、高齢化、糖尿病、喫煙、高血圧、肥満、座りがちなライフスタイルなどの要因と関連しています。PADは、運動時に脚の筋肉への血流を制限し、酸素不足による痛みやけいれんを引き起こします。2023年6月に発行された米国心臓協会雑誌によると、PADは米国で700万～1,200万人、世界で2億人に影響を及ぼしています。このPADの有病率の増加が間欠性跛行市場の拡大を促進しています。

間欠性跛行市場の企業は、末梢動脈疾患や間欠性跛行患者の治療成績を改善するために、RIPK1阻害剤などの先進的な薬物療法の開発に注力しています。これらの治療薬は、血流を促進し、炎症を抑え、疾患の進行を予防することを目的としています。RIPK1阻害剤はRIPK1キナーゼ活性を阻害する標的薬であり、炎症と細胞死を抑制します。2022年8月、中国に本社を置くバイオテクノロジー企業GenFleet社は、間欠性跛行を用いたPADの新規治療薬GFH312の第II相臨床試験を実施する承認を米国食品医薬品局（FDA）から取得しました。この無作為化、二重盲検、プラセボ対照試験は15の研究センターで実施されます。GFH312はRIPK1阻害剤であり、前臨床試験において動物モデルの炎症を抑制することで有望な結果を示しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の間欠性跛行 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の間欠性跛行市場：成長率分析
• 世界の間欠性跛行市場の実績：規模と成長、2019年～2024年
• 世界の間欠性跛行市場の予測：規模と成長、2024年～2029年、2034年
• 世界の間欠性跛行総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の間欠性跛行市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 薬物療法
• 血行再建術
• 世界の間欠性跛行市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 非経口経路
• 経口経路
• その他の投与経路
• 世界の間欠性跛行市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• クリニック
• 在宅ヘルスケア
• その他の用途
• 世界の間欠性跛行市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の間欠性跛行市場、薬物療法の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 抗血小板薬
• 血管拡張薬
• ホスホジエステラーゼ阻害剤
• シロスタゾール
• ペントキシフィリン
• 世界の間欠性跛行市場、血行再建術のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 血管形成術
• ステント留置術
• バイパス手術
• 動脈内膜切除術

第7章 地域別・国別分析

• 世界の間欠性跛行市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の間欠性跛行市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 間欠性跛行市場：競合情勢
• 間欠性跛行市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Merck KGaA
• Teva Pharmaceutical
• Otsuka Pharmaceutical Co. Ltd.
• Sanofi S.A.
• Bayer AG
• Hikma Pharmaceuticals PLC
• Dr. Reddy's Laboratories
• Pipelinepharma
• Pharmaoffer
• Alkem Laboratories
• LGM Pharma
• Aastrid Life Sciences Pvt. Ltd.
• Manus Aktteva Biopharma LLP
• Enomark Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 間欠性跛行市場2029年：新たな機会を提供する国
• 間欠性跛行市場2029年：新たな機会を提供するセグメント
• 間欠性跛行市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Intermittent claudication is a condition marked by muscle pain, cramping, or discomfort in the legs that occurs during physical activity, such as walking, and is relieved by rest. It is usually caused by peripheral artery disease (PAD), which occurs when narrowed or blocked arteries restrict blood flow to the muscles. The pain is typically due to a lack of oxygen (ischemia) in the affected muscles.

The primary treatments for intermittent claudication include medication therapies and revascularization procedures. Medication therapies involve the use of drugs to relieve symptoms, improve blood flow, reduce pain, and prevent complications related to poor circulation. These medications are administered through various methods, such as parenteral, oral, and other routes, and are used in settings such as hospitals, clinics, and home healthcare. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The intermittent claudication market research report is one of a series of new reports from The Business Research Company that provides intermittent claudication market statistics, including the intermittent claudication industry's global market size, regional shares, competitors with a intermittent claudication market share, detailed intermittent claudication market segments, market trends and opportunities, and any further data you may need to thrive in the intermittent claudication industry. This intermittent claudication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The intermittent claudication market size has grown strongly in recent years. It will grow from $12.81 billion in 2024 to $13.64 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to factors such as the rise in peripheral artery disease, increased awareness of vascular diseases, growth in the geriatric population, higher diagnosis rates, and an increase in healthcare spending.

The intermittent claudication market size is expected to see strong growth in the next few years. It will grow to $17.39 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of diabetes, rising obesity rates, growing prevalence of cardiovascular diseases, higher alcohol and tobacco consumption, and increasing healthcare spending. Key trends in the forecast period include advancements in PAD diagnostics, the integration of wearable devices, the incorporation of personalized medicine, a shift toward drug-eluting stents, and progress in stem cell therapy.

The rising incidence of peripheral artery disease (PAD) is expected to drive the growth of the intermittent claudication market in the coming years. PAD is a circulatory condition where narrowed arteries reduce blood flow to the limbs, causing pain, numbness, and other complications. The increasing number of PAD cases is linked to factors such as an aging population, diabetes, smoking, hypertension, obesity, and sedentary lifestyles. PAD leads to intermittent claudication by limiting blood flow to the leg muscles during physical activity, resulting in pain and cramping due to a lack of oxygen. According to the American Heart Association Journals, published in June 2023, PAD affects 7 to 12 million people in the U.S. and 200 million people worldwide. This growing prevalence of PAD is driving the expansion of the intermittent claudication market.

Companies in the intermittent claudication market are focusing on developing advanced medication therapies, such as RIPK1 inhibitors, to improve treatment outcomes for patients with peripheral artery disease and intermittent claudication. These therapies aim to enhance blood flow, reduce inflammation, and prevent disease progression. RIPK1 inhibitors are targeted drugs that block RIPK1 kinase activity, which helps reduce inflammation and cell death. In August 2022, GenFleet, a biotechnology company based in China, received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial for GFH312, a new treatment for PAD with intermittent claudication. This randomized, double-blind, placebo-controlled study will take place at 15 research centers. GFH312 is a RIPK1 inhibitor that has shown promising results in preclinical studies by reducing inflammation in animal models.

In April 2023, Abbott Laboratories, a healthcare company based in the U.S., acquired Cardiovascular Systems Inc. for $890 million. This acquisition is aimed at expanding Abbott's vascular device portfolio by incorporating Cardiovascular Systems Inc.'s advanced technologies for treating peripheral and coronary artery disease. The acquisition strengthens Abbott's position in the cardiovascular market and improves patient care with innovative, minimally invasive solutions. Cardiovascular Systems Inc. is a U.S.-based medical device company known for its innovative treatments for peripheral artery disease, including intermittent claudication.

Major players in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, and Pharmacompass.

North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intermittent claudication report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intermittent claudication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intermittent claudication market includes revenues earned by entities by providing services such as non-invasive tests, angioplasty, stent placement, supervised exercise therapy, and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The intermittent claudication market also consists of sales of antiplatelet agents, statins, vasodilators, and special socks or stockings. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intermittent Claudication Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intermittent claudication market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intermittent claudication ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intermittent claudication market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Medication Therapies; Revascularization
• 2) By Route Of Administration: Parenteral Route; Oral Route; Other Routes Of Administration
• 3) By Application: Hospitals; Clinics; Home Healthcare; Other Applications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Medication Therapies: Antiplatelet Agents; Vasodilators; Phosphodiesterase Inhibitors; Cilostazol; Pentoxifylline
• 2) By Revascularization: Angioplasty; Stenting; Bypass Surgery; Endarterectomy
• Companies Mentioned: Pfizer Inc.; Bristol Myers Squibb Company; AstraZeneca PLC; Novartis AG; GSK plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Intermittent Claudication Market Characteristics

3. Intermittent Claudication Market Trends And Strategies

4. Intermittent Claudication Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Intermittent Claudication Growth Analysis And Strategic Analysis Framework

• 5.1. Global Intermittent Claudication PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Intermittent Claudication Market Growth Rate Analysis
• 5.4. Global Intermittent Claudication Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Intermittent Claudication Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Intermittent Claudication Total Addressable Market (TAM)

6. Intermittent Claudication Market Segmentation

• 6.1. Global Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication Therapies
• Revascularization
• 6.2. Global Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral Route
• Oral Route
• Other Routes Of Administration
• 6.3. Global Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Healthcare
• Other Applications
• 6.4. Global Intermittent Claudication Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Intermittent Claudication Market, Sub-Segmentation Of Medication Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiplatelet Agents
• Vasodilators
• Phosphodiesterase Inhibitors
• Cilostazol
• Pentoxifylline
• 6.6. Global Intermittent Claudication Market, Sub-Segmentation Of Revascularization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angioplasty
• Stenting
• Bypass Surgery
• Endarterectomy

7. Intermittent Claudication Market Regional And Country Analysis

• 7.1. Global Intermittent Claudication Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Intermittent Claudication Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intermittent Claudication Market

• 8.1. Asia-Pacific Intermittent Claudication Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intermittent Claudication Market

• 9.1. China Intermittent Claudication Market Overview
• 9.2. China Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intermittent Claudication Market

• 10.1. India Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intermittent Claudication Market

• 11.1. Japan Intermittent Claudication Market Overview
• 11.2. Japan Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intermittent Claudication Market

• 12.1. Australia Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intermittent Claudication Market

• 13.1. Indonesia Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intermittent Claudication Market

• 14.1. South Korea Intermittent Claudication Market Overview
• 14.2. South Korea Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intermittent Claudication Market

• 15.1. Western Europe Intermittent Claudication Market Overview
• 15.2. Western Europe Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intermittent Claudication Market

• 16.1. UK Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intermittent Claudication Market

• 17.1. Germany Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intermittent Claudication Market

• 18.1. France Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intermittent Claudication Market

• 19.1. Italy Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intermittent Claudication Market

• 20.1. Spain Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intermittent Claudication Market

• 21.1. Eastern Europe Intermittent Claudication Market Overview
• 21.2. Eastern Europe Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intermittent Claudication Market

• 22.1. Russia Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intermittent Claudication Market

• 23.1. North America Intermittent Claudication Market Overview
• 23.2. North America Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intermittent Claudication Market

• 24.1. USA Intermittent Claudication Market Overview
• 24.2. USA Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intermittent Claudication Market

• 25.1. Canada Intermittent Claudication Market Overview
• 25.2. Canada Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intermittent Claudication Market

• 26.1. South America Intermittent Claudication Market Overview
• 26.2. South America Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intermittent Claudication Market

• 27.1. Brazil Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intermittent Claudication Market

• 28.1. Middle East Intermittent Claudication Market Overview
• 28.2. Middle East Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intermittent Claudication Market

• 29.1. Africa Intermittent Claudication Market Overview
• 29.2. Africa Intermittent Claudication Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Intermittent Claudication Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Intermittent Claudication Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intermittent Claudication Market Competitive Landscape And Company Profiles

• 30.1. Intermittent Claudication Market Competitive Landscape
• 30.2. Intermittent Claudication Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

31. Intermittent Claudication Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Merck KGaA
• 31.3. Teva Pharmaceutical
• 31.4. Otsuka Pharmaceutical Co. Ltd.
• 31.5. Sanofi S.A.
• 31.6. Bayer AG
• 31.7. Hikma Pharmaceuticals PLC
• 31.8. Dr. Reddy's Laboratories
• 31.9. Pipelinepharma
• 31.10. Pharmaoffer
• 31.11. Alkem Laboratories
• 31.12. LGM Pharma
• 31.13. Aastrid Life Sciences Pvt. Ltd.
• 31.14. Manus Aktteva Biopharma LLP
• 31.15. Enomark Pharma

32. Global Intermittent Claudication Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intermittent Claudication Market

34. Recent Developments In The Intermittent Claudication Market

35. Intermittent Claudication Market High Potential Countries, Segments and Strategies

• 35.1 Intermittent Claudication Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Intermittent Claudication Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Intermittent Claudication Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer